According to Jin10, Citi analysts said Sanofi’s top-selling drug Dupixent could face competition in the coming years from AstraZeneca’s tozorakimab, Pfizer’s tilrekimig, and zumilokibart from AbbVie and Apogee. Developed jointly by Sanofi and Regeneron, Dupixent helped Sanofi’s third-quarter results exceed expectations. Citi forecasts that Dupixent sales growth will slow from an estimated 32% this year to 12% in 2027, and that its pricing advantage may no longer drive growth after 2027. Citi raised its price target for Sanofi from 78 euros to 93 euros.